Literature DB >> 8322383

Evaluation of the combination of a tissue-type plasminogen activator, SUN9216, and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.

K Umemura1, K Wada, T Uematsu, M Nakashima.   

Abstract

BACKGROUND AND
PURPOSE: We aimed to evaluate a modified tissue-type plasminogen activator, SUN9216, and the combination of SUN9216 and a thromboxane A2 receptor antagonist, vapiprost, in a rat middle cerebral artery thrombosis model.
METHODS: Under anesthesia, the left middle cerebral artery was observed under an operation microscope without cutting the dura mater via a subtemporal craniotomy. Photoillumination (wave length, 540 nm) was applied to the middle cerebral artery, and then rose bengal (20 mg/kg) was administered intravenously. The reopening of the middle cerebral artery by SUN9216, injected 30 minutes after middle cerebral artery occlusion, was observed under an operation microscope for a 60-minute observation period. Twenty-four hours after the operation, sections of the cerebrum were stained with triphenyltetrazolium chloride, and the area of cerebral infarction was analyzed by a computer.
RESULTS: The combination of SUN9216 and vapiprost caused reopening of the middle cerebral artery in 58.8% of the rats, which was a greater percentage than that achieved with SUN9216 alone (31.6%). In contrast, saline did not cause reopening of the middle cerebral artery during the 60-minute observation period. The area of cerebral infarction in rats reperfused with SUN9216 was significantly reduced compared with that in the control group. The infarction area in rats treated with the combination of SUN9216 and vapiprost was reduced compared with that in rats treated with SUN9216 alone; this was the case whether or not the occlusion was reperfused. There was a significant correlation between the time of reopening of the middle cerebral artery and area of cerebral infarction.
CONCLUSIONS: A single injection of SUN9216 was effective in recanalizing the vessel and reducing the area of cerebral infarction.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8322383     DOI: 10.1161/01.str.24.7.1077

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  5 in total

1.  Rat cerebral ischemia induced with photochemical occlusion of proximal middle cerebral artery: a stroke model for MR imaging research.

Authors:  Feng Chen; Yasuhiro Suzuki; Nobuo Nagai; Ronald Peeters; Xihe Sun; Walter Coudyzer; Guy Marchal; Yicheng Ni
Journal:  MAGMA       Date:  2004-10-26       Impact factor: 2.310

2.  A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates.

Authors:  Yuko Izuhara; Nagahisa Yamaoka; Hidehiko Kodama; Takashi Dan; Shunya Takizawa; Noriaki Hirayama; Kanji Meguro; Charles van Ypersele de Strihou; Toshio Miyata
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

3.  Pericytes contribute to the disruption of the cerebral endothelial barrier via increasing VEGF expression: implications for stroke.

Authors:  Ying Bai; Xinjian Zhu; Jie Chao; Yuan Zhang; Cheng Qian; Peicheng Li; Dongfang Liu; Bing Han; Lei Zhao; Jianqiong Zhang; Shilpa Buch; Gaojun Teng; Gang Hu; Honghong Yao
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

4.  Different exercises can modulate the differentiation/maturation of neural stem/progenitor cells after photochemically induced focal cerebral infarction.

Authors:  Saho Morishita; Kazuya Hokamura; Akira Yoshikawa; Nobuhide Agata; Yoshihiro Tsutsui; Kazuo Umemura; Tatsuro Kumada
Journal:  Brain Behav       Date:  2020-01-27       Impact factor: 2.708

5.  Precise Characterization of the Penumbra Revealed by MRI: A Modified Photothrombotic Stroke Model Study.

Authors:  Cheng Qian; Pei-Cheng Li; Yun Jiao; Hong-Hong Yao; Yu-Chen Chen; Jian Yang; Jie Ding; Xiang-Yu Yang; Gao-Jun Teng
Journal:  PLoS One       Date:  2016-04-19       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.